Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Forte Biosciences Inc (FBRX)

Forte Biosciences Inc (FBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,204
  • Shares Outstanding, K 36,395
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,480 K
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.80
Trade FBRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.04
  • Most Recent Earnings $-0.04 on 03/18/24
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 297.13% ( +22.55%)
  • Historical Volatility 49.02%
  • IV Percentile 25%
  • IV Rank 17.31%
  • IV High 1,320.58% on 03/11/24
  • IV Low 82.95% on 04/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 259
  • Open Int (30-Day) 265

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +312,287.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6200 +19.13%
on 04/08/24
0.7800 -5.31%
on 04/19/24
+0.0382 (+5.45%)
since 03/22/24
3-Month
0.4400 +67.86%
on 02/05/24
0.7800 -5.31%
on 04/19/24
+0.0486 (+7.04%)
since 01/23/24
52-Week
0.3800 +94.37%
on 11/14/23
1.1497 -35.76%
on 05/03/23
-0.3314 (-30.97%)
since 04/21/23

Most Recent Stories

More News
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.87 (+2.19%)
INCY : 51.65 (-0.52%)
SGEN : 228.74 (-0.07%)
PFE : 26.32 (+0.23%)
FBRX : 0.7386 (+2.58%)
JAZZ : 109.67 (+0.77%)
ALC : 80.76 (+0.19%)
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.87 (+2.19%)
INCY : 51.65 (-0.52%)
BMY : 48.99 (-0.31%)
SGEN : 228.74 (-0.07%)
FBRX : 0.7386 (+2.58%)
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a business update.

FBRX : 0.7386 (+2.58%)
Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors.

FBRX : 0.7386 (+2.58%)
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update.

FBRX : 0.7386 (+2.58%)
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors.

FBRX : 0.7386 (+2.58%)
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise

Camac Partners, LLC (together with its affiliates, "Camac" or “we”), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”), today expressed...

FBRX : 0.7386 (+2.58%)
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced second quarter 2022 results and provided a business update.

FBRX : 0.7386 (+2.58%)
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer...

FBRX : 0.7386 (+2.58%)
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq...

FBRX : 0.7386 (+2.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.

See More

Key Turning Points

3rd Resistance Point 0.8241
2nd Resistance Point 0.7955
1st Resistance Point 0.7671
Last Price 0.7386
1st Support Level 0.7101
2nd Support Level 0.6815
3rd Support Level 0.6531

See More

52-Week High 1.1497
Fibonacci 61.8% 0.8557
Fibonacci 50% 0.7649
Last Price 0.7386
Fibonacci 38.2% 0.6740
52-Week Low 0.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar